Document is current
Any future updates will be listed below
-
Authors
Canna, Scott W.
Schulert, Grant S.
de Jesus, Adriana
Pickering, Alex
Brunner, Hermine
Gadina, Massimo
Levine, Stewart
Goldbach-Mansky, Raphaela
Boutelle, Jonathan
Sinha, Rashmi
DeBenedetti, Fabrizio
Grom, Alexei
,
Gottlieb, Beth
Yeung, Rae
Riskalla, Mona
Prahalad, Sampath
Alehashemi, Sara
Chandrakasan, Shan
Vastert, Bas
Kimura, Yuki
Carlson, Anna
Schumacher, Emily
Minerva, Regina
Pierce, Jonathan
Pierce, Kate
Martinez, Zulayka
Cupp, Kari
Bush, Leah
Costello, Wendy
DelGaizo, Vincent
-
Funding
Funding for this research was provided by:
SJIA Foundation
- License Information
-
More Information
Article History
Received: 26 May 2020
Accepted: 17 June 2020
First Online: 15 July 2020
Ethics approval and consent to participate
: Not applicable.
: All authors have reviewed the manuscript and provided their consent to publish. All the patients mentioned in the manuscript gave their permissions to use full names.
: Dr. Canna received clinical trial support from AB2Bio. Dr. Schulert has received consulting fees from SOBI and Novartis (less than $10,000 each). Dr. Brunner has received consulting fees from Bristol-Myers Squibb, Pfizer, Janssen, Eli Lilly, Roche, and Novartis (less than $10,000 each). Dr. Grom has received consulting fees from SOBI and Novartis (less than $10,000 each) and research support from SOBI, Novartis, and AB2 Bio. Dr. Gadina has a Collaborative Research and Development Agreement related to JAK inhibitors with Pfizer. Dr. De Benedetti has received research grants from Abbvie, Pfizer, Eli-Lilly, Roche, Novartis, NovImmune, Sanofi, and SOBI. Dr. Rashmi Sinha serves as the president of <i>the SJIA Foundation</i>. No other disclosures relevant to this article were reported.
